TX-MOBIL-1/FORZA-MTRSPRT
25.7.2024 23:52:29 CEST | Business Wire | Press release
Today, the Mobil 1 brand, the world's leading synthetic engine oil, announced its expanded collaboration with Forza Motorsport, the best-selling and most-awarded racing video game franchise, in which gamers and race fans around the world will be able to compete against professional motorsports drivers such as racing legend Tony Stewart and recent INDY NXT winner Jamie Chadwick. Beginning July 25, 2024, gamers and motorsports fans will have the unique opportunity to compete against these drivers on Maple Valley, a United States-themed, Mobil 1-branded, in-game track. Additional professional race car drivers will be announced later this year for gamers to compete against in upcoming Legend vs. Leaderboard Rival Events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725776163/en/
Motorsports icons including Tony Stewart and Jamie Chadwick to race gamers in-game and on-track in Legend vs. Leaderboard Rival Events. (Graphic: Business Wire)
The collaboration continues the celebration of the Mobil 1 brand’s 50th anniversary through exclusive branded content, a chance to win incredible prizes, and the opportunity to beat iconic motorsports driver’s timed laps on the 4.81km virtual course. The Forza Motorsport collaboration marks the Mobil 1 brand’s largest campaign in the video game entertainment space and celebrates both the Mobil 1 team’s 50-year legacy and its longstanding passion for racing.
Kicking off the Legend vs. Leaderboard Rival Events is racing legend Tony Stewart, an American motorsports icon. From July 25 to August 7, 2024, gamers will have the chance to try to beat Stewart’s time on the Maple Valley virtual racetrack. Fans can also look forward to exclusive content on Mobil 1 Racing social media channels – part of a Legend vs. Leaderboard Rival Events social media series – showcasing Stewart setting his time to beat while driving a classic 1969 Ford Mustang Boss 302. New celebrity drivers will be featured in the content series throughout the remainder of 2024. Each month, a new legendary driver will take on the Maple Valley track, providing ongoing challenges, new prizes, and additional content for audiences to enjoy.
“We are thrilled to bring this iconic collaboration to life with Forza Motorsport to continue the celebration of the Mobil 1 brand's historic 50th anniversary,” said Laura Bustard, Global Brand Manager, on behalf of the Mobil 1 team. “This collaboration signifies our continued commitment to innovation and excellence in motorsports while also showcasing our passion for racing beyond a physical racetrack but increasingly in the virtual world. We are proud to have created a dynamic and immersive experience for gamers and race fans that allows us to celebrate our legacy, and we cannot wait to see fans share in the excitement by racing against a variety of professional motorsports drivers.”
Later this summer, the next Legends vs. Leaderboard Rivals Event series will take place and feature British racing driver Jamie Chadwick. From August 29 through September 11, 2024, gamers will have the opportunity to race against the rising motorsports star. Chadwick will be racing a 1967 Corvette as she invites the global Forza Motorsport audience to join her in-game for the chance to beat her timed lap.
Forza Motorsport, created by Turn 10 Studios and Xbox Game Studios, continues to be one of the premier racing games by giving players an opportunity to participate in racing events around a variety of both real and fictional tracks – including some of their favorite tracks – available in-game. As the Mobil 1 brand continues to grow within the gaming space and curate incredible experiences for driving enthusiasts, the Forza Motorsport relationship serves as a key milestone to reach new audiences and provide unique virtual automotive experiences – all while sharing its love of driving at a global level.
The Legends vs. Leaderboard Rival Events will kick off on July 25 and run through December 11, 2024 with five different events for gamers and race fans to participate in.
To stay up to date and learn more about this collaboration, visit https://promotions.mobil.com/offers/Mobil1Gaming-forza. Also, stay tuned for driver announcements and exclusive content on @Mobil1Racing on Instagram and X.
About Mobil 1
For 50 years, the Mobil 1 brand has been trusted by drivers to help keep their engines running longer. Our products combine the latest technology and innovation to exceed the toughest standards of vehicle manufacturers and tuning shops—so consumers can get the most out of their time behind the wheel, both on the road and on the track. Turn every day into an adventure with Mobil 1 products, the world’s leading synthetic motor oil brand. Learn more at www.mobil1.us or and follow @Mobil1Racing on Instagram and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725776163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom